PMID

Data

Article Title

Organization

NO-sartans: a new class of pharmacodynamic hybrids as cardiovascular drugs.

Universit£

 

Substituted lactam biphenyltetrazoles as angiotensin II mediated antihypertensives

TBA

 

Synthesis and In Vitro evaluation of fused ring heterocyle-containing angiotensin II antagonists.

TBA

Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT1 receptor antagonists.

School of Chemical Engineering & The Environment

Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.

Universit£

Quantized surface complementarity diversity (QSCD): a model based on small molecule-target complementarity.

Neogenesis

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.

Dupont Pharmaceuticals

Excursions in drug discovery.

Merck Research Laboratories

 

L-161,638: A potent AT2selective quinazolinone angiotensin II binding inhibitor

TBA

 

(6-oxo-3-pyridazinyl)-benzimidazoles as potent angiotensin II receptor antagonists

TBA

Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists.

Kyung Hee University

Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists.

Beijing Institute of Technology

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.

The M. S. University of Baroda

 

The design, binding affinity prediction and synthesis of macrocyclic angiotensin II AT₁ and AT₂ receptor antagonists

TBA

 

L-162,389: a potent orally active angiotensin II receptor antagonist with balanced affinity to both AT₁ and AT₂ receptor subtypes

TBA

 

AT₁ selective angiotensin II antagonists with phenoxyphenylacetic acid as a biphenyl replacement part I

TBA

 

The SAR of 6-(N-alkyl-N-acyl)-2-propyl-3-[(2′-tetrazol-5-yl)biphen-4-yl)methyl]-quinazolinones as balanced affinity antagonists of the human AT₁ and AT₂ receptors

TBA

 

α-Phenoxyphenylacetic acid derived angiotensin II antagonists with low nanomolar AT₁/AT₂ receptor subtype affinity (Part II)

TBA

 

Substituted 1,3-benzodioxole & 1,3-benzodithiole -2- carboxylates and their tetrazole analogs with potent binding affinity to the angiotensin II AT₁ receptor

TBA

 

Potent triazolinone-based angiotensin II receptor antagonists with equivalent affinity for both the AT₁ and AT₂ subtypes

TBA

 

Development of angiotensin II antagonists with equipotent affinity for human AT₁ and AT₂ receptor subtypes.

TBA

 

A new class of balanced AT₁/AT₂ angiotensin II antagonists: quinazolinone AII antagonists with acylsulfonamide and sulfonylcarbamate acidic functionalities

TBA

 

Quinazolinone Biphenyl Acylsulfonamides: A potent new class of angiotensin-II receptor antagonists

TBA

 

Potent imidazole angiotensinII antagonists: acyl sulfonamides and acyl sulfamides as tetrazole replacements

TBA

 

Evaluation of heterocyclic acid equivalents as tetrazole replacements in imidazopyridine-based nonpeptide angiotensin II receptor antagonists

TBA

 

Synthesis of new imidazo[1,2-b]pyridazine isosteres of potent imidazo[4,5-b]pyridine angiotensin II antagonists

TBA

 

Acidic phenols: a new class of potent nonpeptide angiotensin II receptor antagonists

TBA

 

Subtituted phenylthiophene benzoylsulfonamides with potent binding affinity to angiotensin II AT₁ and AT₂ receptors

TBA

 

Imidazo[4,5-b]pyridine-based AT₁ / AT₂ angiotensin II receptor antagonists

TBA

 

Triazolinones as nonpeptide angiotensin II antagonists. 2. discovery of a potent and orally active triazolinone acylsulfonamide

TBA

 

Angiotensin II receptor antagonists containing a phenylpyridine element.

TBA

 

Quinazolinones 2: QSAR and in vivo characterization of AT1 selective AII antagonists

TBA

 

Quinazolinones 1: design and synthesis of potent quinazolinone- containing AT₁-selective angiotensin-II receptor antagonists

TBA

 

Synthesis and structure-activity relationships of a novel series of non-peptide AT₂-selective angiotensin II receptor antagonists

TBA

Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds.

Università

Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies.

Tianjin University

Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.

Merck Research Laboratories

Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones.

Merck Research Laboratories

Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides.

Merck Research Laboratories

Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles.

Merck Research Laboratories

(Dipropylphenoxy)phenylacetic acids: a new generation of nonpeptide angiotensin II receptor antagonists.

Merck Research Laboratories

Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.

Merck Research Laboratories

A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor.

Merck Research Laboratories

Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.

Merck Research Laboratories

A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.

Merck Research Laboratories

Triazolinone biphenylsulfonamides as angiotensin II receptor antagonists with high affinity for both the AT1 and AT2 subtypes.

Merck Research Laboratories

Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.

Merck Research Laboratories